CN101367807B - Sulfhydryl pyrrolidine formamido pyridine substituted penem derivant - Google Patents

Sulfhydryl pyrrolidine formamido pyridine substituted penem derivant Download PDF

Info

Publication number
CN101367807B
CN101367807B CN2008101293413A CN200810129341A CN101367807B CN 101367807 B CN101367807 B CN 101367807B CN 2008101293413 A CN2008101293413 A CN 2008101293413A CN 200810129341 A CN200810129341 A CN 200810129341A CN 101367807 B CN101367807 B CN 101367807B
Authority
CN
China
Prior art keywords
hydrogen atom
represent hydrogen
methyl
represented
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008101293413A
Other languages
Chinese (zh)
Other versions
CN101367807A (en
Inventor
黄振华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xuanzhu Biopharmaceutical Co Ltd
Original Assignee
Shandong Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Xuanzhu Pharma Co Ltd filed Critical Shandong Xuanzhu Pharma Co Ltd
Priority to CN2008101293413A priority Critical patent/CN101367807B/en
Publication of CN101367807A publication Critical patent/CN101367807A/en
Application granted granted Critical
Publication of CN101367807B publication Critical patent/CN101367807B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

The present invention belongs to the technical field of medicine, and in particular relates to a penem derivative substituted by sulfhydryl pyrrolidine carbamoyl pyridine as shown in Formula (I), an acceptable salt thereof in pharmacy, an easily hydrolyzed ester thereof, an isomer thereof, a hydrate thereof, and a hydrate of ester or salt thereof; wherein, R<1>, R<2>, R<3>, R<4> , R<5> and R<6> are defined as in the specification. The present invention also relates to the preparation methods of the compounds, drug compositions of the compounds, and the application of the compounds in preparation of medicine which is used for treating and/or preventing infectious diseases.

Description

The Pennem derivates that sulfhydryl pyrrolidine formamido pyridine replaces
1, technical field
The invention belongs to medical technical field, be specifically related to the hydrate of ester, its isomer, its hydrate and the ester or the salt of Pennem derivates that sulfhydryl pyrrolidine formamido pyridine replaces, its pharmacy acceptable salt, its facile hydrolysis, the preparation method of these compounds, the pharmaceutical composition that contains these compounds, and these compounds are in the purposes that is used for preparing the medicine that treats and/or prevents infectious diseases.
2, background technology
Carbapenem antibiotic is the class β-Nei Xiananleikangshengsu that the seventies grows up.Because of its has a broad antifungal spectrum, anti-microbial activity is strong, and stable to β-Nei Xiananmei, and receives much concern.Its constructional feature is, the sulphur that the penam parent nucleus is 1 is replaced by carbon, and 2 have two keys, the effect of the five-ring of compound penicillin and the conjugated double bond activation beta-lactam nucleus of cynnematin; 6 hydroxyethyl side chains are transoid conformation.
This similar drug that has gone on the market at present has imipenum, meropenem, S-4661, biapenem, ertapenem etc.Because antibiotic abuse causes the continuous increase of bacterial drug resistance, and because the limitation that digestive tube absorbs, the carbapenems of listing clinically can only be as the injection administration at present, clinical availability is not high, and except that ertapenem the transformation period all shorter, can not meet clinical needs.
Therefore, be badly in need of research and development and have better antibacterial activity, and have the long-acting carbapenem antibiotic of good chemical stability and DHP-I stability.
3, summary of the invention
Technical scheme of the present invention is as follows:
The invention provides the hydrate of ester, its isomer, its hydrate and the ester or the salt of the compound shown in the general formula (1), its pharmacy acceptable salt, its facile hydrolysis:
Figure S2008101293413D00011
Wherein, R 1Represent hydrogen atom or carboxyl-protecting group;
R 2Represent hydrogen atom or amino protecting group;
R 3Represent hydrogen atom or low alkyl group;
R 4, R 5Independently represent hydrogen atom or low alkyl group respectively;
R 6Represent hydrogen atom, halogen atom, cyano group, hydroxyl, amino, formamyl, amino-sulfonyl, replaced or unsubstituted low alkyl group by halogen atom, amino, hydroxyl, lower alkoxy, low alkyl group amido alkylsulfonyl, low alkyl group amido formyl radical, low alkyl group sulfoamido, perhaps low alkyl group amide group;
R 7Represent hydrogen atom or low alkyl group;
Q, Y independently represent N or CH respectively.
Preferred compound is:
Wherein, R 1Represent hydrogen atom or carboxyl-protecting group,
Described carboxyl-protecting group is selected from methyl, ethyl, the tertiary butyl, methoxymethyl, first thiomethyl, benzyloxymethyl, phenacyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R 2Represent hydrogen atom or amino protecting group,
Described amino protecting group is selected from methyl, ethyl, the tertiary butyl, benzyl, formyl radical, ethanoyl, allyloxy carbonyl, phenacyl, tert-butoxycarbonyl, to the nitro benzyloxycarbonyl, to methoxyl group benzyloxy base carbonyl, 3-acetoxyl group propyl group or diazo;
R 3Represent hydrogen atom, methyl or ethyl;
R 4, R 5Independently represent hydrogen atom respectively, methyl, ethyl or propyl group;
R 6Represent hydrogen atom, fluorine atom, chlorine atom, cyano group, hydroxyl, amino, formamyl, amino-sulfonyl, trifluoromethyl, low alkyl group, lower alkoxy, methyl amido formyl radical, methylsulfonyl amido or acetamido;
R 7Represent hydrogen atom, methyl or ethyl;
Q, Y independently represent N or CH respectively.
Further preferred compound is:
Wherein, R 1Represent hydrogen atom or carboxyl-protecting group,
Described carboxyl-protecting group is selected from methyl, the tertiary butyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R 2Represent hydrogen atom or amino protecting group,
Described amino protecting group is selected from methyl, the tertiary butyl, formyl radical, allyloxy carbonyl, tert-butoxycarbonyl, to the nitro benzyloxycarbonyl, to methoxyl group benzyloxy base carbonyl or diazo;
R 3Represent hydrogen atom or methyl;
R 4, R 5Independently represent hydrogen atom or methyl respectively;
R 6Represent hydrogen atom or low alkyl group;
R 7Represent hydrogen atom or methyl;
Q, Y independently represent N or CH respectively.
" halogen atom " of the present invention is fluorine atom, chlorine atom, bromine atoms or iodine atom.
" low alkyl group " of the present invention is C 1-6The alkyl of straight or branched is as methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, amyl group, neo-pentyl, hexyl etc.
" lower alkoxy " of the present invention is C 1-6The alkoxyl group of straight or branched comprises methoxyl group, oxyethyl group, positive propoxy, isopropoxy, n-butoxy, tert.-butoxy, n-pentyloxy, positive hexyloxy etc.
" low-grade alkyl amino alkylsulfonyl " of the present invention is C 1-6Alkyl amino sulfonyl comprises first sulfamyl, second sulfamyl etc.
" elementary alkyl amido methanoyl " of the present invention is C 1-6Alkyl-carbamoyl comprises methylamino formyl radical, ethylamino formyl radical etc.
" low alkyl group sulfonamido " of the present invention is C 1-6Alkyl sulfonyl amino comprises methanesulfonamido, ethanesulfonamido etc.
" low alkyl group amido " of the present invention is C 1-6Alkyl amido comprises kharophen, propionamido etc.
" carboxyl-protecting group " of the present invention refers to that routine is used for the blocking group of substituted carboxylic acid acid proton.This examples of groups comprises: methoxymethyl, the first thiomethyl, THP trtrahydropyranyl, tetrahydrofuran base, the methoxyethyl methyl, benzyloxymethyl, phenacyl, allyl group, to bromobenzene formyl methyl, the Alpha-Methyl phenacyl, to the methoxybenzoyl methyl, the diacyl methyl, the N-phthalimidomethyl, methyl, ethyl, diphenyl methyl, 2,2,2-three chloroethyls, the 2-halogenated ethyl, ω-chloro alkyl, 2-(trimethyl silyl) ethyl, 2-methylmercaptoethyl, 2-(p-nitrophenyl sulfenyl) ethyl, 2-(to the toluene sulfenyl) ethyl, 1-methyl isophthalic acid-styroyl, the tertiary butyl, cyclopentyl, cyclohexyl, two (ortho-nitrophenyl base) methyl, 9-fluorenyl methyl, 2-(9, the 10-dioxo) fluorenyl methyl, 5-hexichol sulfenyl, benzyl, 2,4, the 6-trimethyl benzyl, to bromobenzyl, adjacent nitrobenzyl, to nitrobenzyl, to methoxy-benzyl, piperonyl, the 4-picolyl, trimethyl silyl, triethylsilyl, t-butyldimethylsilyl, the sec.-propyl dimetylsilyl, the phenyl dimetylsilyl, the S-tertiary butyl, the S-phenyl, the S-2-pyridyl, N-hydroxy piperidine base, N-hydroxyl succinimido, N-hydroxyl phthaloyl imino, N-hydroxybenzotriazole base, O-acyl group oxime, 2,4-dinitrobenzene sulfenyl, 2-alkyl-1, the 3-oxazoline, 4-alkyl-5-oxo-1, the 3-oxazolidine, 5-alkyl-4-oxo-1, the 3-diox, the triethyl stannane, tri-n-butyl stannane; N, N '-di-isopropyl hydrazides etc.
" amino protecting group " of the present invention refers to that routine is used for the blocking group of substituted-amino acid proton, this type of examples of groups comprises: methyl, ethyl, encircle third methyl, 1-methyl isophthalic acid-ring third methyl, the diisopropyl methyl, the 9-fluorene methyl, 9-(2-sulfo-) fluorene methyl, furfuryl, 2,2, the 2-trichloromethyl, the 2-halogenated methyl, 2-iodine ethyl, 2-trimethyl silyl ethyl, 2-methylmercaptoethyl, 2-methylsulfonyl ethyl, 2-(p-toluenesulfonyl) ethyl, 2-phosphorus base ethyl, 1,1-dimethyl-3-(N, N-dimethylformamide base) propyl group, 1,1-phenylbenzene-3-(N, the N-diethylin) propyl group, 1-methyl isophthalic acid-(adamantyl) ethyl, 1-methyl isophthalic acid-styroyl, 1-methyl isophthalic acid-(3, the 5-dimethoxy phenyl) ethyl, 1-methyl isophthalic acid-(4-xenyl) ethyl, 1-methyl isophthalic acid-(to the phenylazo-phenyl) ethyl, 1,1-dimethyl-2,2,2-three chloroethyls, 1,1-dimethyl-2-cyanoethyl, isobutyl-, the tertiary butyl, tert-pentyl, cyclobutyl, 1-methyl cyclobutyl, cyclopentyl, cyclohexyl, the 1-methylcyclohexyl, the 1-adamantyl, isobornyl, vinyl, allyl group, cinnamyl, phenyl, 2,4,6-tri-tert phenyl, the m-nitro base, the S-phenyl, the 8-quinolyl, N '-hydroxy piperidine base, 4-(1,4-lupetidine base), 4,5-phenylbenzene-3-oxazoline-2-ketone, benzyl, 2,4, the 6-trimethyl benzyl, to methoxy-benzyl, to methoxyl group benzyloxy base carbonyl, 3, the 5-dimethoxy-benzyl, to oxy-benzyl in the last of the ten Heavenly stems, to nitrobenzyl, to the nitro benzyloxycarbonyl, adjacent nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, to bromobenzyl, the benzyl chloride base, 2, the 4-dichloro benzyl, to the cyano group benzyl, adjacent (N, N-dimethylformamide base) benzyl, between-chloro-is right-the acyloxy benzyl, to (dihydroxyl boryl) benzyl, to (phenylazo-) benzyl, to (to the anisole azo-group) benzyl, 5-benzoisoxazole ylmethyl, 9-anthryl methyl, diphenyl-methyl, phenyl (ortho-nitrophenyl base) methyl, two (2-pyridyl) methyl, 1-methyl isophthalic acid-(4-pyridyl) ethyl, the isonicotine base, the S-benzyl, the fixed basic carbonyl of N '-piperazine, the carbamate of N '-p-toluenesulfonyl aminocarboxyl and N '-phenylamino thiocarbonyl; Formyl radical, ethanoyl, ethanoyl-pyridine, (N '-the dithio benzyloxycarbonyl amino) ethanoyl, 3-phenyl propionyl, 3-(to hydroxyphenyl) propionyl, 3-(ortho-nitrophenyl base) propionyl, 2-methyl-2-(ortho-nitrophenyl oxygen base) propionyl, 2-methyl-2-(adjacent phenylazo-phenoxy group) propionyl, 4-chloro butyryl radicals, isobutyryl, adjacent nitro cinnamoyl, the pyridine formyl radical, N '-acetyl methionyl, N '-benzoyl-phenylalkyl, benzoyl, to the phenyl benzoyl, to anisoyl, o-nitrobenzoyl, the acid amides of adjacent (benzoyloxy methyl) benzoyl and right-P-benzoyl; Phthaloyl, 2, the inferior acid amides of the ring of 3-phenylbenzene maleoyl and dithio succinyl; Tert-butoxycarbonyl; allyloxy carbonyl; phenacyl; 3-acetoxyl group propyl group; 4-nitro-1-cyclohexyl-2-oxo-3-tetramethyleneimine-3-base; quaternary ammonium salt; methoxymethyl; 2-chloroethoxy methyl; benzyloxymethyl; the valeryl methyl; [1-(alkoxycarbonyl amido)]-2; 2; 2; trifluoroethyl; [1-Trifluoromethyl-1-(to the chlorophenoxy methoxyl group) 2; 2; 2;-trifluoro] ethyl; the 2-THP trtrahydropyranyl; 2; the 4-dinitrophenyl; benzyl; 3; the 4-dimethoxy-benzyl; adjacent nitrobenzyl; two (p-methoxyphenyl) methyl; trityl; (p-methoxyphenyl) diphenyl methyl; phenylbenzene-4-pyridylmethyl; 2-picolyl-N '-oxide compound; 5-two phenylpropyl alcohol suberane bases; N '; N '-dimethylaminomethylene; N '-isopropylidene; benzylidene; to the methoxyl group benzylidene; to the nitro benzylidene; salicylidene; 5-chlorine salicylidene; diphenylmethylene; (5-chloro-2-hydroxyphenyl) phenylmethylene; (acyl group vinyl); 5; 6-dimethyl-3-oxo-1-cyclohexenyl; borine; [phenyl (pentacarbonyl chromium or tungsten)] carbonyl; copper or chelates of zinc; nitro; nitroso-group; oxide compound; diphenylphosphino; diformazan sulfenyl phosphinyl; hexichol sulfenyl phosphinyl; the diethyl phosphoryl; the dibenzyl phosphoryl; the diphenylphosphine acyl group; phosphoryl; trimethyl silyl; thiophenyl; the ortho-nitrophenyl sulfenyl; 2; 4-dinitrobenzene sulfenyl; 2-nitro-4-anisole sulfenyl; three benzylthios; benzenesulfonyl; to the anisole alkylsulfonyl; 2; 4,6-Three methyl Benzene alkylsulfonyl; methyl sulphonyl; the benzene methylsulfonyl; to the toluene methylsulfonyl; trifluoromethyl sulfonyl; the phenacyl alkylsulfonyl; diazo etc.
Further preferred compound is as follows:
Chemical name: (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [(N, N-dimethyl nicotinamide-5-yl) amino]-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxylic acid, hereinafter to be referred as compound 1, structural formula is as follows:
Chemical name: (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(N, N-lutidine methane amide-6-yl) amino]-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxylic acid, hereinafter to be referred as compound 2, structural formula is as follows:
Figure S2008101293413D00052
The present invention also provides the preparation method of above-claimed cpd:
Reaction equation:
Figure S2008101293413D00053
Reactions steps:
The preparation of step 1 compd B
Add raw material 1 in the exsiccant reaction flask, anhydrous tetrahydro furan is under the nitrogen protection; add 1 in room temperature, 1-carbonyl dimidazoles (CDI), reaction; low temperature adds the acetone soln of raw material 2, continues reaction, then dripping hydrochloric acid; with ethyl acetate extraction, organic phase is water, saturated nacl aqueous solution washing successively, concentrating under reduced pressure; resistates adds hydrochloric acid, stirs, and is adjusted to alkalescence with dilute alkaline soln; separate out solid, solid promptly gets compd B with the mixing solutions recrystallization of acetonitrile-hexanaphthene.
The preparation of step 2 Compound C
In the dry reaction bottle, add the acetonitrile solution of raw material 3, cooling, the acetonitrile solution of adding diisopropylethylamine and compd B, stir, after reaction finishes, add the ethyl acetate dilution, tell organic layer, organic layer is water, saturated salt washing successively, and drying concentrates, and gets Compound C.
The preparation of step 3 Compound D
To go up step gained Compound C and be dissolved in the methylene dichloride, and add methyl-phenoxide and Nitromethane 99Min., low temperature drips the Nitromethane 99Min. solution of aluminum chloride, stir, add entry, separate out solid, filter, filter cake is dissolved in the mixed solution of THF and water, add palladium-charcoal, stirring reaction under the room temperature hydrogen pressure, filtering palladium charcoal adds THF in the filtrate, layering, collect water layer, in THF, add magnesium chloride brine again, leave standstill, divide water-yielding stratum, repetitive operation, water merges, and slowly splashes into methyl alcohol, stir, filter, filter cake water-Virahol recrystallization gets Compound D.
R in the above reaction equation 3, R 4, R 5, R 6, R 7, Q, Y the representative group as mentioned before, the carboxyl on the Compound D can be protected by carboxyl-protecting group, the hydrogen atom on the nitrogen-atoms can be protected by amino protecting group.
The above-mentioned arbitrary compound pharmacy acceptable salt of the present invention is organic acid salt, inorganic acid salt, organic alkali salt or inorganic base salts, and wherein organic acid comprises acetate, trifluoroacetic acid, methylsulfonic acid, toluenesulphonic acids, toxilic acid, succsinic acid, tartrate, citric acid, fumaric acid; Mineral acid comprises hydrochloric acid, Hydrogen bromide, nitric acid, sulfuric acid, phosphoric acid; Organic bases comprises meglumine, glucosamine; Mineral alkali comprises the basic cpd of sodium, potassium, barium, calcium, magnesium, zinc, lithium.
The ester that the claimed compound of the present invention is easy to hydrolysis is the compound that its carboxyl exists with the ester group form that is easy to hydrolysis.These esters can be conventional, lower alkane acyloxyalkyl group ester for example, acetyl-o-methyl ester, pivalyl oxygen methyl ester, 1-acetyl 2-ethoxyethyl acetate and 1-pivalyl 2-ethoxyethyl acetate; Lower alkoxycarbonyl oxyalkyl ester, methoxycarbonyl oxygen methyl ester, 1-ethoxycarbonyl-oxygen ethyl ester, the different third oxygen ketonic oxygen ethyl ester of 1-; The lactone group ester, cumarone ketone group ester, sulfo-benzo furanonyl ester; The lower alkoxy methyl ester, methoxymethyl ester; Lower alkane acyl amino methyl ester, the acetylamino methyl ester.The ester that also can use other is for example: benzyl ester and cyano methyl ester.Other examples of these esters are as follows: (2,2-dimethyl-1-oxygen propoxy-) methyl ester; (1RS)-1-acetoxyl group ethyl ester; 2-[(2-methyl propoxy-) carbonyl]-the pentenyl ester; The 1-[[(1-methyl ethoxy) carbonyl] oxygen] ethyl ester; 1-(acetoxyl) ethyl ester; (5-methyl-2-oxo-1,3-dioxole-4-yl) methyl ester; The 1-[[(cyclohexyloxy) carbonyl] oxygen] ethyl ester; 3,3-dimethyl-2-oxo butyl ester.It is evident that for the professional of this area the ester that is easy to hydrolysis of The compounds of this invention can form at the free carboxy place of this compound.
Isomer of the present invention is meant its all differences to stereoisomerism, diastereo-isomerism and tautomeric form.When a key was represented with a wedge, this showed that this key will come out from paper on three-dimensional, and when a key was shade, this showed that this key will return in the paper on three-dimensional.Formula (1) compound has many three-dimensional centers, as on the 4-position; On the 5-position; On the 6-position.
The ester of the compound shown in the general formula (1), its pharmacy acceptable salt, its facile hydrolysis, its isomer can be hydrate forms.Hydration can be finished in preparation process or can be utilized the water absorbability of original anhydrous product to carry out gradually.
The present invention is further claimed to comprise the hydrate of ester, its isomer, its hydrate or its ester or salt of arbitrary compound recited above, its pharmacy acceptable salt, its facile hydrolysis and the pharmaceutical composition of other active pharmaceutical ingredients, as cilastatin and sodium salt thereof, Betamipron.
The present invention is further claimed to comprise the hydrate of ester, its isomer, its hydrate or its ester or salt of arbitrary compound recited above, its pharmacy acceptable salt, its facile hydrolysis and the pharmaceutical composition of one or more pharmaceutical carriers and/or thinner; for clinically or pharmaceutically acceptable arbitrary formulation, be preferably oral preparations or injection.Wherein contain the compound 0.05g～5g shown in the general formula (1) of physiology significant quantity, can be 0.05g, 0.1g, 0.125g, 0.2g, 0.25g, 0.3g, 0.4g, 0.5g, 0.6g, 0.75g, 1g, 1.25g, 1.5g, 1.75g, 2g, 2.5g, 3g, 4g, 5g etc.
The hydrate of the ester of The compounds of this invention, its pharmacy acceptable salt, its facile hydrolysis, its isomer, its hydrate and ester or salt, can be oral or mode such as administered parenterally be applied to the patient who needs this treatment.
When being used for administered parenterally, can be made into injection.Injection means the intravital solution of confession injection, emulsion or the suspension that medicine is made and supplies to face with preceding preparation or be diluted to solution or the sterile preparation of the powder of suspension or strong solution that injection can be divided into injection liquid, injectable sterile powder and concentrated solution for injection.Injection liquid means that the confession that medicine is made is injected into sterile solution type injection liquid, emulsion-type injection liquid or the suspension type injection liquid of using in the body, can be used for intramuscularly, intravenous injection, intravenous drip etc.; Its specification has 1ml, 2ml, 5ml, 10ml, 20ml, 50ml, 100ml, 200ml, 250ml, 500ml etc., and wherein large volume (generally the being not less than 100ml) injection liquid of using for intravenous drip also claims intravenous infusion.Injectable sterile powder means that confession that medicine is made is faced with the suitable sterile solution of preceding usefulness and is mixed with settled solution or the evenly sterilized powder or the aseptic block of suspension, available suitable solvent for injection preparation back injection, also available intravenous infusion preparation posterior vein instils; Sterilized powder makes with solvent crystallization, spray-drying process or freeze-drying etc.Concentrated solution for injection means that confession that medicine is made faces the aseptic strong solution of using for intravenous drip with preceding dilution.
When making injection, can adopt the ordinary method production in the existing pharmacy field, optional use solvent or non-aqueous solvent.The most frequently used aqueous solvent is a water for injection, also available 0.9% sodium chloride solution or other suitable aqueous solution; Non-aqueous solvent commonly used is a vegetables oil, is mainly the injection soybean oil, and other also have the aqueous solution of ethanol, propylene glycol, polyoxyethylene glycol etc.During the preparation injection, can not add additives, also can add suitable additives, as osmotic pressure regulator, pH value conditioning agent, solubilizing agent, weighting agent, oxidation inhibitor, fungistat, emulsifying agent, suspending agent etc. according to the character of medicine.Osmotic pressure regulator commonly used comprises sodium-chlor, glucose, Repone K, magnesium chloride, calcium chloride, sorbyl alcohol etc., preferred sodium-chlor or glucose; PH value conditioning agent commonly used comprises acetic acid-sodium-acetate, lactic acid, Citric Acid-Sodium Citrate, sodium bicarbonate-yellow soda ash etc.; Solubilizing agent commonly used comprises Polysorbate 80, propylene glycol, Yelkin TTS, polyoxyethylenated castor oil etc.; Weighting agent commonly used comprises lactose, N.F,USP MANNITOL, sorbyl alcohol, dextran etc.; Oxidation inhibitor commonly used has S-WAT, sodium bisulfite, Sodium Pyrosulfite etc.; Fungistat commonly used is phenol, cresols, trichloro-butyl alcohol etc.Injection container commonly used has glass ampoule, vial, plastic ampoule, Plastic Bottle etc.
Be used for when oral, can be made into conventional solid preparation, as tablet, capsule, pill, granule etc.; Also can be made into oral liquid, as oral solution, oral suspensions, syrup etc.Tablet means disk shape or the special-shaped flaky solid preparation that medicine and the auxiliary materials and mixing compacting that suits form, based on oral ordinary tablet, other has lozenge, Sublingual tablet, mouth paster, chewable tablet, dispersible tablet, fuse, effervescent tablet, slow releasing tablet, controlled release tablet and enteric coated tablet etc.Capsule means medicine or is added with the auxiliary material filling in Capsules or be sealed in solid preparation in the soft capsule material, according to its dissolving and release characteristics, can be divided into hard capsule (being commonly referred to as capsule), soft capsule (capsule and pill), slow releasing capsule, controlled release capsule and enteric coated capsule etc.Pill means medicine and suitable auxiliary material uniform mixing, and the spherical or near-spherical solid preparation so that proper method is made comprises dripping pill, sugar-pill, piller etc.Granule means that medicine and suitable auxiliary material make the dried particles shape preparation with certain particle size, can be divided into soluble particles (being commonly referred to as particle), mix suspension grain, effervescent granule, enteric coated particles, slow-releasing granules and controlled release granule etc.Oral solution means that medicine dissolution makes for oral clarified liq preparation in suitable solvent.Oral suspensions means the insoluble solid pharmaceutical, is dispersed in the liquid medium, makes for oral suspension body preparation, also comprises dry suspensoid or dense suspension.Syrup means the dense aqueous sucrose solution that contains medicine.
When making oral preparations, can add suitable weighting agent, tackiness agent, disintegrating agent, lubricant etc.Weighting agent commonly used comprises starch, Icing Sugar, calcium phosphate, calcium sulfate two water things, dextrin, Microcrystalline Cellulose, lactose, pregelatinized Starch, N.F,USP MANNITOL etc.; Typical binders comprises Xylo-Mucine, PVP-K30, hydroxypropylcellulose, starch slurry, methylcellulose gum, ethyl cellulose, hypromellose, gelling starch etc.; Disintegrating agent commonly used comprises dry starch, polyvinylpolypyrrolidone, croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropyl cellulose etc.; Conventional lubricants comprises Magnesium Stearate, talcum powder, sodium lauryl sulphate, micropowder silica gel etc.
Usually, have been found that carbapenems is nontoxic to warm-blooded animal, and this general rule also is applicable to The compounds of this invention.With preferred compound of the present invention preventing the needed excessive dosage of infectation of bacteria to the mouse administration, not to be noted significantly poison aura or side effect.
The present invention also provide Pennem derivates of the present invention preparation be used for the treatment of and/or the medicine of prophylaxis against infection diseases in purposes.Pennem derivates of the present invention all has better antibacterial activity to gram-positive microorganism and negative bacterium, aerophil and anerobe and hospital clinical pathogenic bacteria such as Pseudomonas aeruginosa and acinetobacter bacterium, can be used for treating and/or preventing the various diseases that causes by pathogenic micro-organism, as respiratory tract infection and urinary tract infection.
The Pennem derivates that relates to the sulfhydryl pyrrolidine formamido pyridine replacement of the present invention is compared with immediate prior art, has the following advantages:
(1) The compounds of this invention has good anti-microbial activity and shows hypotoxicity, can being used for the treatment of and/or preventing various Mammalss (comprising the mankind) by the caused various diseases of sensitive organism by safety;
(2) The compounds of this invention has a broad antifungal spectrum, gram-positive microorganism and negative bacterium, aerophil and anerobe and hospital clinical pathogenic bacteria all there is better antibacterial activity, especially the resistance Pseudomonas aeruginosa there is better antibacterial activity, and MRSA is had certain activity;
(3) The compounds of this invention has high stability to β-Nei Xiananmei and DHP-I, can be used for β-Nei Xiananmei and produces bacterium, and do not need to share with other medicines;
(4) The compounds of this invention preparation technology is simple, and medicine purity height, yield height, steady quality are easy to carry out large-scale commercial production.
Below further set forth the beneficial effect of the Pennem derivates that sulfhydryl pyrrolidine formamido pyridine of the present invention replaces by in-vitro antibacterial experiment, but this should be interpreted as that the southern analog derivative of training of the present invention only has following beneficial effect.
The antibacterial activity in vitro of experimental example The compounds of this invention
For the examination bacterial classification: below be the clinical isolates strain, purchase in public institution.
Gram positive organism: MSSA (MSSA) 18 strains, methicillin-resistant staphylococcus aureus (MRSA) 15 strains, methicillin-sensitivity staphylococcus epidermidis (MSSE) 25 strains, methicillin-resistant staphylococcus epidermidis (MRSE) 13 strains, responsive streptococcus pneumoniae (PSSP) 20 strains of penicillin, penicillin resistance streptococcus pneumoniae (PRSP) 15 strains, streptococcus pyogenes 16 strains, enterococcus faecalis 12 strains;
Gram-negative bacteria: hemophilus influenzae 12 strains, escherichia coli 18 strains, klepsiella pneumoniae 15 strains, Proteus mirabilis 17 strains, enterobacter cloacae 15 strains, Pseudomonas aeruginosa 15 strains; Grain-negative anerobe: bacteroides fragilis 8 strains.
Trial-product:
Preferred compound 1 of the present invention and compound 2, self-control, its chemical name and structural formula are as mentioned before;
Imipenum, meropenem: commercial.
Experimental technique: agar dilution, with reference to " pharmacological testing methodology " P1659-1660, People's Health Publisher, chief editor: Xu Shuyun etc., release: the 1st edition the 3rd edition the 5th printing January in 2002 in August nineteen eighty-two.
Experimental result and conclusion:
Table 1 The compounds of this invention is to the anti-microbial activity of clinical separation gram positive organism
Figure S2008101293413D00101
By table 1 experimental result as seen, compare with meropenem with imipenum, 2 pairs of clinical isolating examination gram positive organisms that supply of The compounds of this invention 1 and compound all have the excellent antibiotic activity.
Table 2 The compounds of this invention is to the anti-microbial activity of clinical separation gram-negative bacteria
Figure S2008101293413D00102
By table 2 experimental result as seen, compare with meropenem with imipenum, 2 pairs of The compounds of this invention 1 and compounds are clinical isolating for the examination gram-negative bacteria, comprise that the Grain-negative anerobe has the excellent antibiotic activity.
Above-mentioned experimental result shows, The compounds of this invention all has potent anti-microbial effect to gram positive organism, negative bacterium and resistant organism thereof and anerobe, compares with immediate prior art, and anti-microbial activity quite or better, and has a broad antifungal spectrum has the good clinical application potential.
4, embodiment
The embodiment of form is described in further detail foregoing of the present invention by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following examples.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.The auxiliary material of each formulation can be replaced with acceptable accessories in following examples, perhaps reduces, increases.
Embodiment 1 (2S, 4S)-4-sulfydryl-2-formyl [(N, N-dimethyl nicotinamide-5-yl) amino]-1-(tertbutyloxycarbonyl) tetramethyleneimine Preparation
In the exsiccant reaction flask, add (2S; 4S)-4-acetylthio-2-carboxyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 5.8g (20mmol); anhydrous tetrahydro furan 80ml; under the nitrogen protection; add 1 in room temperature, 1-carbonyl dimidazoles 4.9g (30mmol), reaction 1h; adding 4.1g (25mmol) 5-amino-N below 0 ℃; the acetone soln of N-dimethyl nicotinamide continues reaction 0.5h, drips 1mol/L hydrochloric acid 40ml then; extract with ethyl acetate (50ml * 2); organic phase is water successively; the saturated nacl aqueous solution washing, concentrating under reduced pressure, resistates adds the hydrochloric acid 100ml of 5mol/L; stir 2h; be adjusted to alkalescence with dilute alkaline soln, separate out solid, solid is with acetonitrile-hexanaphthene (1: 1) mixing solutions recrystallization; get solid 6.7g, yield: 85.1%.
Embodiment 2 (2S, 4S)-4-sulfydryl-2-formyl [(N, N-lutidine methane amide-6-yl) amino]-1-(tertbutyloxycarbonyl) pyrrole Cough up the preparation of alkane
Concrete operations reference example 1, throw (2S, 4S)-4-acetylthio-2-carboxyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 5.8g (20mmol), 6-amino-N, N-lutidine methane amide 4.1g (25mmol), (2S, 4S)-4-sulfydryl-2-formyl [(N, N-lutidine methane amide-6-yl) amino]-1-(tertbutyloxycarbonyl) tetramethyleneimine 6.6g, yield: 83.4%.
Embodiment 3 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(N, N-dimethyl nicotinamide-5-yl) amino]-1-(tertbutyloxycarbonyl) Tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy Preparation
In the reaction flask, add (4R, 5S, 6S)-3-hexichol oxygen phosphorus acyloxy-6-[(1R)-1-hydroxyethyl]-the acetonitrile solution 120ml of 4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 11.9g (20mmol), be chilled to below-10 ℃, add diisopropylethylamine 5ml and (2S, 4S)-the acetonitrile solution 80ml of 4-sulfydryl-2-formyl [(N, N-dimethyl nicotinamide-5-yl) amino]-1-(tertbutyloxycarbonyl) tetramethyleneimine 8.7g (22mmol), 0 ℃ is stirred 15h, after reaction finishes, add ethyl acetate 300ml dilution, successively water, the saturated salt washing, the organic layer drying, concentrate, get solid 10.4g, yield: 70.7%.
Embodiment 4 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(N, N-lutidine methane amide-6-yl) amino]-1-(tertiary butyloxycarbonyl Base) tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxylic acid is to nitro The preparation of benzyl ester
Concrete preparation method's reference example 3.Throw (4R, 5S, 6S)-3-hexichol oxygen phosphorus acyloxy-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 11.9g (20mmol), (2S, 4S)-4-sulfydryl-2-formyl [(N, N-lutidine methane amide-6-yl) amino]-1-(tertbutyloxycarbonyl) tetramethyleneimine 8.7g (22mmol).Get product 10.2g, yield: 69.2%.
Embodiment 5 (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [(N, N-dimethyl nicotinamide-5-yl) amino]-tetramethyleneimine-4-yl] sulphur Base-6-[(1R)-1-hydroxyethyl]-preparation of 4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxylic acid
Will (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [(N, N-dimethyl nicotinamide-5-yl) amino]-1-(tertbutyloxycarbonyl) tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 7.4g (10mmol) is dissolved in the 50ml methylene dichloride, adds methyl-phenoxide 10ml and Nitromethane 99Min. 20ml, in-50 ℃ of Nitromethane 99Min. solution 100ml that drip the 1mol/L aluminum chloride down,-40 ℃ are stirred 2h, add entry 200ml, separate out solid, filter, filter cake is dissolved in the mixed solution of 400ml THF and water 30ml, add 10% palladium-charcoal 2g, stirring reaction 2h under the room temperature 5MPa hydrogen pressure, filtering palladium charcoal, add THF 150ml in the filtrate, water layer is collected in layering, adds 5% magnesium chloride brine 20ml again in THF, leave standstill, divide water-yielding stratum, repetitive operation 1 time, water merges, 0 ℃ slowly splashes into methyl alcohol 30ml,-10 ℃ are stirred 1h, filter filter cake water-Virahol recrystallization, get white crystal 2.3g, yield: 46.4%.
Molecular formula: C 23H 29N 5O 6S
Molecular weight: 503.57
Ultimate analysis:
Measured value: C, 54.67%; H, 6.06%; N, 13.77%; S, 6.21%
Theoretical value: C, 54.86%; H, 5.80%; N, 13.91%; S, 6.37%
Embodiment 6 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(N, N-lutidine methane amide-6-yl) amino]-tetramethyleneimine-4-yl] Sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxylic acid preparation
Concrete preparation method's reference example 5.Throw (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(N, N-lutidine methane amide-6-yl) amino]-1-(tertbutyloxycarbonyl) tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 7.4g (10mmol).Get white crystal 2.4g, yield: 48.5%.
Molecular formula: C 23H 29N 5O 6S
Molecular weight: 503.57
Ultimate analysis:
Measured value: C, 54.73%; H, 6.02%; N, 13.83%; S, 6.18%
Theoretical value: C, 54.86%; H, 5.80%; N, 13.91%; S, 6.37%
The preparation of embodiment 7 The compounds of this invention aseptic powder injections
1, prescription:
Prescription 1:
Compound 1 or 2 250g (in compound)
Prepare 1000 altogether
Prescription 2:
Compound 1 or 2 500g (in compound)
Prepare 1000 altogether
Prescription 3:
Compound 1 or 2 1000g (in compound)
Prepare 1000 altogether
Prescription 4:
Compound 1 or 2 2000g (in compound)
Prepare 1000 altogether
2, preparation technology:
(1) will prepare used antibiotic glass bottle, plug etc. and carry out aseptically process;
(2) take by weighing raw material (feeding intake after the conversion) by prescription, sterilized powder is placed the portioning machine packing, detect loading amount at any time;
(3) jump a queue, gland, finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 8 The compounds of this invention tablets
1, prescription:
Prescription 1:
Compound 1 or 2 250g (in compound)
Pregelatinized Starch 50g
Low-substituted hydroxypropyl cellulose 40g
Microcrystalline Cellulose 40g
The 2%HPMC aqueous solution is an amount of
Micropowder silica gel 4.0g
Magnesium Stearate 4.0g
Carboxymethylstach sodium 2.0g
Prepare 1000 altogether
Prescription 2:
Compound 1 or 2 125g (in compound)
Pregelatinized Starch 50g
Low-substituted hydroxypropyl cellulose 40g
Microcrystalline Cellulose 40g
The 2%HPMC aqueous solution is an amount of
Micropowder silica gel 4.0g
Magnesium Stearate 4.0g
Carboxymethylstach sodium 2.0g
Prepare 1000 altogether
2, preparation technology:
(1) raw material pulverizing is crossed 100 mesh sieves, all the other auxiliary materials are crossed 100 mesh sieves respectively, and are standby;
(2) take by weighing raw material and auxiliary material according to recipe quantity;
(3) hypromellose 2% the aqueous solution made soluble in water is standby;
(4) compound 1 or 2, pregelatinized Starch, low-substituted hydroxypropyl cellulose, Microcrystalline Cellulose are mixed, the adding 2%HPMC aqueous solution is an amount of, stirs, and makes suitable softwood;
(5) cross 20 mesh sieve system particles;
(6) particle is dried under 60 ℃ condition;
(7) dry good particle adds Magnesium Stearate, micropowder silica gel and carboxymethylstach sodium, crosses the whole grain of 18 mesh sieves, mixes;
(8) sampling, the work in-process chemical examination;
(9) the sheet weight sheet of determining according to chemical examination;
(10) finished product is examined entirely, the packing warehouse-in.

Claims (9)

1. the compound shown in the general formula (1), its pharmacy acceptable salt:
Figure FSB00000263875100011
Wherein, R 1Represent hydrogen atom;
R 2Represent hydrogen atom;
R 3Represent hydrogen atom or C 1-6The alkyl of straight or branched;
R 4, R 5Independently represent hydrogen atom or C respectively 1-6The alkyl of straight or branched;
R 6Represent hydrogen atom or C 1-6The alkyl of straight or branched;
R 7Represent hydrogen atom or C 1-6The alkyl of straight or branched;
Q, Y independently represent N or CH respectively, and when Q represented N, Y represented CH, and perhaps when Q represented CH, Y represented N.
2. compound as claimed in claim 1, its pharmacy acceptable salt:
Wherein, R 1Represent hydrogen atom;
R 2Represent hydrogen atom;
R 3Represent hydrogen atom, methyl or ethyl;
R 4, R 5Independently represent hydrogen atom respectively, methyl, ethyl or propyl group;
R 6Represent hydrogen atom;
R 7Represent hydrogen atom, methyl or ethyl;
Q, Y independently represent N or CH respectively, and when Q represented N, Y represented CH, and perhaps when Q represented CH, Y represented N.
3. compound as claimed in claim 2, its pharmacy acceptable salt:
Wherein, R 1Represent hydrogen atom;
R 2Represent hydrogen atom;
R 3Represent hydrogen atom or methyl;
R 4, R 5Independently represent hydrogen atom or methyl respectively;
R 6Represent hydrogen atom;
R 7Represent hydrogen atom or methyl;
Q, Y independently represent N or CH respectively, and when Q represented N, Y represented CH, and perhaps when Q represented CH, Y represented N.
4. compound as claimed in claim 3, its pharmacy acceptable salt, described compound is selected from:
(4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [(N, N-dimethyl nicotinamide-5-yl) amino]-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxylic acid, perhaps
(4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [(N, N-lutidine methane amide-6-yl) amino]-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo [3,2,0] hept-2-ene"-2-carboxylic acid.
5. each described compound of claim 1～4, its pharmacy acceptable salt, feature is that its pharmacy acceptable salt is organic acid salt, inorganic acid salt, organic alkali salt or inorganic base salts.
6. the pharmaceutical composition that comprises each described compound of claim 1～4, its pharmacy acceptable salt and one or more pharmaceutical carriers and/or thinner.
7. pharmaceutical composition as claimed in claim 6, this pharmaceutical composition are pharmaceutically acceptable arbitrary formulation.
8. pharmaceutical composition as claimed in claim 6 contains each described compound of claim 1～4, its pharmacy acceptable salt 0.05g～5g as essential activeconstituents.
9. each described compound of claim 1～4, its pharmacy acceptable salt are in the application that is used for preparing the medicine that treats and/or prevents infectious diseases.
CN2008101293413A 2007-06-28 2008-06-28 Sulfhydryl pyrrolidine formamido pyridine substituted penem derivant Active CN101367807B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008101293413A CN101367807B (en) 2007-06-28 2008-06-28 Sulfhydryl pyrrolidine formamido pyridine substituted penem derivant

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200710015306 2007-06-28
CN200710015306.4 2007-06-28
CN2008101293413A CN101367807B (en) 2007-06-28 2008-06-28 Sulfhydryl pyrrolidine formamido pyridine substituted penem derivant

Publications (2)

Publication Number Publication Date
CN101367807A CN101367807A (en) 2009-02-18
CN101367807B true CN101367807B (en) 2011-01-12

Family

ID=40411832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008101293413A Active CN101367807B (en) 2007-06-28 2008-06-28 Sulfhydryl pyrrolidine formamido pyridine substituted penem derivant

Country Status (1)

Country Link
CN (1) CN101367807B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079224A (en) * 1992-02-04 1993-12-08 曾尼卡有限公司 Antifungal compound
CN1225636A (en) * 1996-07-12 1999-08-11 麦克公司 Process for synthesizing carbapenem atnibiotics
CN1486318A (en) * 2001-01-16 2004-03-31 Improved process for carbapenem synthesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1079224A (en) * 1992-02-04 1993-12-08 曾尼卡有限公司 Antifungal compound
CN1225636A (en) * 1996-07-12 1999-08-11 麦克公司 Process for synthesizing carbapenem atnibiotics
CN1486318A (en) * 2001-01-16 2004-03-31 Improved process for carbapenem synthesis

Also Published As

Publication number Publication date
CN101367807A (en) 2009-02-18

Similar Documents

Publication Publication Date Title
CN101372489B (en) Carbapenem derivative containing sulfhydryl pyrrolidine formamide benzyl
CN101525336B (en) Carbapenem compound containing substituted formohydrazide group
CN101362760B (en) 1beta-methyl carbapenem compound
CN101333217A (en) 1-methyl carbapenem antibiotics
CN101367804B (en) Penem derivant containing adamantane
CN101367807B (en) Sulfhydryl pyrrolidine formamido pyridine substituted penem derivant
CN101323615B (en) Pennem derivates containing formamide heterocycle sulfonic acid amide sulfhydryl pyrrolidine
CN101357918B (en) Penem derivative containing isothioureido sulfhydryl pyrrolidine
CN101367817B (en) Carbpenem compound containing cyclohexenone formamido group
CN101367814B (en) Sulfhydryl pyrrolidine formyl piperidine substituted penem derivant
CN101367809B (en) Penem derivant containing sulfhydryl pyrrolidine formhydrazide
CN101367812B (en) Sulfhydryl pyrrolidine formamido cyclopentene acid substituted penem derivant
CN101357920B (en) Penem derivative containing sulfhydryl pyrrolidine formamido triazine
CN101367811B (en) Carbon substituted penems antibiotics
CN101367816B (en) Carbpenem derivants
CN101343271B (en) Penem derivant containing isoxazole alkyl ketone
CN101357919B (en) Penem derivative containing sulfhydryl formamide benzenesulfonyl pyrrolidine
CN101333219B (en) Penem derivates with mercapto pyrrolidine formamide benzene alkyl heterocycle
CN101328179B (en) Sulfhydryl pyrrolidine penem derivates containing oxo aza ring
CN101367810A (en) Novel carbpenem antibiotic
CN101362759B (en) Dihydropyrrole methano substituted carbapenem derivates
CN101343272B (en) Carbpenem compound containing cyclohexane
CN101367805B (en) Formyl guanidino substituted sulfhydryl pyrrolidine carbpenem compounds
CN101260108B (en) Mercaptopyrrolidone carbon penems derivatives
CN101372488A (en) Novel carbapenem compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190108

Address after: 570105 Tianyi International Building, 85 Binhai Avenue, Longhua District, Haikou City, Hainan Province, 27th Floor

Patentee after: Hainan Xuanzhu Pharmaceutical Technology Co., Ltd.

Address before: 250101 No. 2518 Tianchen Street, Jinan High-tech Development Zone, Shandong Province

Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd.

TR01 Transfer of patent right
CP03 Change of name, title or address

Address after: 050000 Beijing Tianjin Hebei Collaborative Innovation Demonstration Park, 769 Taihang street, high tech Zone, Shijiazhuang City, Hebei Province 203c507

Patentee after: Xuanzhu Biotechnology Co., Ltd

Address before: 570105 Tianyi International Building, 85 Binhai Avenue, Longhua District, Haikou City, Hainan Province, 27th Floor

Patentee before: Hainan Xuanzhu Pharma Co.,Ltd.

CP03 Change of name, title or address
CP01 Change in the name or title of a patent holder

Address after: 050000 Beijing Tianjin Hebei Collaborative Innovation Demonstration Park 203c507, 769 Taihang street, high tech Zone, Shijiazhuang City, Hebei Province

Patentee after: Xuanzhu Biotechnology Co.,Ltd.

Address before: 050000 Beijing Tianjin Hebei Collaborative Innovation Demonstration Park 203c507, 769 Taihang street, high tech Zone, Shijiazhuang City, Hebei Province

Patentee before: Xuanzhu Biotechnology Co.,Ltd.

CP01 Change in the name or title of a patent holder